Download PDF
Exp Clin Endocrinol Diabetes
DOI: 10.1055/a-2549-6889
Article

Association of FGF21 with Metabolic and Cardiovascular Diseases: A Mendelian Randomization Analysis

Qingwen He‡
1   Affiliated Womenʼs Hospital of Jiangnan University, Wuxi, China (Ringgold ID: RIN680653)
,
Yuguang Li‡
1   Affiliated Womenʼs Hospital of Jiangnan University, Wuxi, China (Ringgold ID: RIN680653)
,
Renqiang Yu
1   Affiliated Womenʼs Hospital of Jiangnan University, Wuxi, China (Ringgold ID: RIN680653)
,
Mengyuan Lin
1   Affiliated Womenʼs Hospital of Jiangnan University, Wuxi, China (Ringgold ID: RIN680653)
› Author AffiliationsSupported by: Science Foundation of Health Commission of Wuxi.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Introduction

Studies have covered a possible relevance between fibroblast growth factor 21 (FGF21) and obesity-related metabolic complications and cardiovascular disease (CVD). Nevertheless, whether FGF21 is a causative factor in these diseases is not known. Using a bidirectional, two-sample Mendelian randomization (MR) approach, this study sought to establish a causal relationship between FGF21 and seven metabolic diseases and six CVDs.

Methods

A large-scale meta-analysis dataset of genome-wide association studies (GWAS) was analyzed to generate summary-level statistics for FGF21. The diseases we studied included non-alcoholic fatty liver disease (NAFLD), obesity, type 2 diabetes (T2DM), hypertension, gestational diabetes (GDM), gestational hypertension (GHTN), pre-eclampsia or eclampsia (PE), atherosclerosis, cardiomyopathy (CMP), coronary heart disease (CHD), coronary atherosclerosis, heart failure (HF), myocardial infarction (MI) and the corresponding summary GAWS data were retrieved from the FinnGen Biobank and IEU Open GWAS Project database. The inverse variance-weighted (IVW) algorithm was the primary approach utilized for the MR analysis. The MR-Egger regression and MR-PRESSO tests were implemented to evaluate horizontal pleiotropy. The heterogeneity of instrumental variables was subsequently assessed utilizing Cochranʼs Q statistics.

Results

When diseases are used as exposures, MR analysis results of the IVW method indicated that NAFLD (Beta=− 0.047, 95% CI=− 0.08 to − 0.014; p=0.006), obesity (Beta=0.087, 95% CI=0.021–0.153; p=0.009), T2DM (Beta=0.071, 95% CI=0.037–0.106; p<0.001) correlated causally with FGF21. Nevertheless, FGF21 was not causally related to the remaining metabolic diseases and CVDs, according to the results of the MR analysis (p>0.05). It was demonstrated that the aforementioned results were robust and devoid of pleiotropy.

Conclusions

Our study supports a causal association between NAFLD, obesity, and T2DM with FGF21. No substantial evidence exists to establish a causal relationship between FGF21 and other diseases. This study provides opportunities for the early prevention and innovative therapy of NAFLD, obesity, and T2DM.

Keywords

Autoimmunity - Diabetes - Cardiovascular incidences - Cardiovascular risk management - Obesity

Supplementary Material



Publication History

Received: 04 November 2024

Accepted after revision: 25 February 2025

Article published online:
17 April 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 She QY, Bao JF, Wang HZ. et al. Fibroblast growth factor 21: A "rheostat" for metabolic regulation?. Metabolism 2022; 130: 155166
    CrossrefPubMedSearch in Google Scholar
  • 2 Lu W, Li X, Luo Y. FGF21 in obesity and cancer: New insights. Cancer Lett 2021; 499: 5-13
    CrossrefPubMedSearch in Google Scholar
  • 3 Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: From bench to clinic. Nat Rev Endocrinol 2020; 16: 654-667
    CrossrefPubMedSearch in Google Scholar
  • 4 Zhang Y, Liu D, Long XX. et al. The role of FGF21 in the pathogenesis of cardiovascular disease. Chin Med J (Engl) 2021; 134: 2931-2943
    CrossrefPubMedSearch in Google Scholar
  • 5 Liu C, Schönke M, Spoorenberg B. et al. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis. Elife 2023; 12: e83075
    CrossrefPubMedSearch in Google Scholar
  • 6 Bahijri S, Eldakhakhny B, Enani S. et al. Fibroblast growth factor 21: A more effective biomarker than free fatty acids and other insulin sensitivity measures for predicting non-alcoholic fatty liver disease in Saudi Arabian type 2 diabetes patients. Cureus 2023; 15: e50524
    CrossrefPubMedSearch in Google Scholar
  • 7 Tillman EJ, Rolph T. FGF21: An emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases. Front Endocrinol (Lausanne) 2020; 1: 601290
    CrossrefPubMedSearch in Google Scholar
  • 8 Keipert S, Ost M. Stress-induced FGF21 and GDF15 in obesity and obesity resistance. Trends Endocrinol Metab 2021; 32: 904-915
    CrossrefPubMedSearch in Google Scholar
  • 9 Harrison SA, Abdelmalek MF, Neff G. et al. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): A randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol 2022; 10: 603-616
    CrossrefPubMedSearch in Google Scholar
  • 10 Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep 2018; 20: 12
    CrossrefPubMedSearch in Google Scholar
  • 11 Gaich G, Chien JY, Fu H. et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013; 18: 333-340
    CrossrefPubMedSearch in Google Scholar
  • 12 Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: From bench to clinic. Nat Rev Endocrinol 2020; 16: 654-667
    CrossrefPubMedSearch in Google Scholar
  • 13 Szczepańska E, Gietka-Czernel M. FGF21: A novel regulator of glucose and lipid metabolism and whole-body energy balance. Horm Metab Res 2022; 54: 203-211
    CrossrefPubMedSearch in Google Scholar
  • 14 Flippo KH, Potthoff MJ. Metabolic messengers: FGF21. Nat Metab 2021; 3: 309-317
    CrossrefPubMedSearch in Google Scholar
  • 15 Zhao JH, Stacey D, Eriksson N. et al. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol 2023; 24: 1540-1551
    CrossrefPubMedSearch in Google Scholar
  • 16 Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol 2011; 40: 740-752
    CrossrefPubMedSearch in Google Scholar
  • 17 He Q, Yang Z, Sun Y. et al. The impact of homocysteine on the risk of hormone-related cancers: A Mendelian randomization study. Front Nutr 2021; 8: 645371
    CrossrefPubMedSearch in Google Scholar
  • 18 Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res 2017; 26: 2333-2355
    CrossrefPubMedSearch in Google Scholar
  • 19 Zheng J, Baird D, Borges MC. et al. Recent developments in Mendelian randomization studies. Curr Epidemiol Rep 2017; 4: 330-345
    CrossrefPubMedSearch in Google Scholar
  • 20 Burgess S, Scott RA, Timpson NJ. et al. Using published data in Mendelian randomization: A blueprint for efficient identification of causal risk factors. Eur J Epidemiol 2015; 30: 543-552
    CrossrefPubMedSearch in Google Scholar
  • 21 Bowden J, Davey Smith G, Haycock PC. et al. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 2016; 40: 304-314
    CrossrefPubMedSearch in Google Scholar
  • 22 Brumpton B, Sanderson E, Heilbron K. et al. Avoiding dynastic, assortative mating, and population stratification biases in Mendelian randomization through within-family analyses. Nat Commun 2020; 11: 351
    CrossrefPubMedSearch in Google Scholar
  • 23 Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013; 37: 658-665
    CrossrefPubMedSearch in Google Scholar
  • 24 Verbanck M, Chen CY, Neale B. et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 2018; 50: 693-698
    CrossrefPubMedSearch in Google Scholar
  • 25 Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. J Hepatol 2019; 70: 531-544
    CrossrefPubMedSearch in Google Scholar
  • 26 Nassir F. NAFLD: Mechanisms, treatments, and biomarkers. Biomolecules 2022; 12: 824
    CrossrefPubMedSearch in Google Scholar
  • 27 Markan KR, Naber MC, Ameka MK. et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 2014; 63: 4057-4063
    CrossrefPubMedSearch in Google Scholar
  • 28 Rusli F, Deelen J, Andriyani E. et al. Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice. Sci Rep 2016; 6: 30484
    CrossrefPubMedSearch in Google Scholar
  • 29 Shen Y, Hu T, Tan H. et al. Insight to the association among fibroblast growth factor 21, non-alcoholic fatty liver disease and cardiovascular outcomes: A population-based study. Cytokine 2023; 170: 156318
    CrossrefPubMedSearch in Google Scholar
  • 30 He L, Deng L, Zhang Q. et al. Diagnostic value of CK-18, FGF-21, and related biomarker panel in nonalcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Res Int 2017; 2017: 9729107
    CrossrefPubMedSearch in Google Scholar
  • 31 Alisi A, Ceccarelli S, Panera N. et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. PLoS One 2013; 8: e67160
    CrossrefPubMedSearch in Google Scholar
  • 32 Fisher FM, Chui PC, Antonellis PJ. et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59: 2781-2789
    CrossrefPubMedSearch in Google Scholar
  • 33 Tucker B, Li H, Long X. et al. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. Metabolism 2019; 101: 153994
    CrossrefPubMedSearch in Google Scholar
  • 34 Kharitonenkov A, Shiyanova TL, Koester A. et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-1635
    CrossrefPubMedSearch in Google Scholar
  • 35 Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: From bench to clinic. Nat Rev Endocrinol 2020; 16: 654-667
    CrossrefPubMedSearch in Google Scholar
  • 36 Keuper M, Häring HU, Staiger H. Circulating FGF21 levels in human health and metabolic disease. Exp Clin Endocrinol Diabetes 2020; 128: 752-770
    Thieme ConnectPubMedSearch in Google Scholar
  • 37 Al-Kuraishy HM, Al-Gareeb AI, Saad HM. et al. The potential effect of metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM. Inflammopharmacology 2023; 31: 1751-1760
    CrossrefPubMedSearch in Google Scholar
  • 38 Liu Z, Peng Y, Li S. et al. Increased circulating FGF21 level predicts the burden of metabolic demands and risk of vascular diseases in adults with type 2 diabetes. BMC Endocr Disord 2023; 23: 272
    CrossrefPubMedSearch in Google Scholar
  • 39 Chakhtoura M, Haber R, Ghezzawi M. et al. Pharmacotherapy of obesity: An update on the available medications and drugs under investigation. EClinicalMedicine 2023; 58: 101882
    CrossrefPubMedSearch in Google Scholar
  • 40 Jimenez V, Jambrina C, Casana E. et al. FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol Med 2018; 10: e8791
    CrossrefPubMedSearch in Google Scholar
  • 41 Keipert S, Ost M. Stress-induced FGF21 and GDF15 in obesity and obesity resistance. Trends Endocrinol Metab 2021; 32: 904-915
    CrossrefPubMedSearch in Google Scholar
  • 42 Xu L, Ping F, Yin J. et al. Elevated plasma SPARC levels are associated with insulin resistance, dyslipidemia, and inflammation in gestational diabetes mellitus. PLoS One 2013; 8: e81615
    CrossrefPubMedSearch in Google Scholar
  • 43 de Bont J, Jaganathan S, Dahlquist M. et al. Ambient air pollution and cardiovascular diseases: An umbrella review of systematic reviews and meta-analyses. J Intern Med 2022; 291: 779-800
    CrossrefPubMedSearch in Google Scholar
  • 44 Tan H, Yue T, Chen Z. et al. Targeting FGF21 in cardiovascular and metabolic diseases: From mechanism to medicine. Int J Biol Sci 2023; 19: 66-88
    CrossrefPubMedSearch in Google Scholar
  • 45 Lee CH, Woo YC, Chow WS. et al. Role of circulating fibroblast growth factor 21 measurement in primary prevention of coronary heart disease among Chinese patients with type 2 diabetes mellitus. J Am Heart Assoc 2017; 6: e005344
    CrossrefPubMedSearch in Google Scholar